The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...

In MS trials, investigators are steering those cells toward B‑cell populations that appear to be driving inflammation.

Scientists have built functional cancer-fighting immune cells directly inside living animals, skipping the expensive and time-consuming process of extracting a patient’s cells and engineering them in ...

Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival ...

Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.

Researchers discovered a way to keep T cells from wearing out during the fight against cancer, and the approach could make immune-based treatments far more powerful. They found that tumors use a ...

Immune cells can target cancer in the clinic. The ability to test a gene-editing technology in mice on a large scale should improve such immunotherapies. Michael Hudecek is in the Department of ...